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Abstract: Among the dysfunctions and pathologies associated with sepsis, the 
underlying molecular mechanisms of sepsis-induced acute lung injury (ALI) are poorly 
understood. Endothelin (ET)-1, a potent vasoconstrictor and pro-inflammatory peptide, 
is known to be involved in the pathogenesis of ALI in a rat model of sepsis. Here, we 
investigated whether landiolol hydrochloride, an ultra-short-acting β-blocker, plays a 
crucial role in ameliorating and attenuating LPS-induced ALI through modulation of the 
ET-1 system. Male Wistar rats at 8 weeks of age were administered with either saline or 
lipopolysaccharide (LPS) for three hours (3h) and some of the LPS-administered rats 
were continuously treated with landiolol for 3h. ALI was induced by LPS, including 
levels of both circulatory and pulmonary TNF-α and IL-6 but [PaO2] was significantly 
decreased. LPS also induced a significant increase in levels of pulmonary ET-1 and 
ET-A receptor, but levels of ET-B receptor, which has vasodilating effects, were 
remarkably diminished. Further, LPS administration upregulated the pulmonary 
expression of HIF-1α. Finally, the treatment of LPS-administered rats with landiolol for 
3h ameliorated and prevented ALI, normalized the altered levels of pulmonary ET-1 
and ET-A receptors. Landiolol also induced significant down-regulation of ET-B 
receptor in lung tissues in the early hours (phase) of sepsis. However, Landiolol 
treatment had no effect on the up-regulated inflammatory mediators (TNF-α, IL-6) in 
both plasma and lung tissues during sepsis, and expression of pulmonary HIF-1α also 
remained unchanged after landiolol treatment. Collectively, these data led us to 
conclude that landiolol may ameliorate sepsis-induced ALI via the pulmonary ET 
system. 
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Introduction 
Sepsis is a critical life threatening condition with a definition that encompasses  
pathologic infection and physiological changes that are collectively known as systemic 
inflammatory response syndrome (SIRS) [1]. The mortality from sepsis and the 
associated complications is very high and is estimated to be about 30% [2], making it 
the second leading cause of death among patients admitted at non-coronary intensive 
care units [3]. To date, the pathogenesis of sepsis and its progression to multiple organ 
dysfunction syndrome (MODS) and the associated septic shock are poorly understood 
and thus have been the subject of investigations in the last several decades. 
Acute lung injury (ALI) is a well-known and frequent complication of sepsis, and 
causes a significant number of sudden deaths (mortality) and morbidity [4–6]. For this 
reason, patients with ALI/ARDS account for a significant proportion of the intensive 
care unit (ICU) case load. ALI and acute respiratory distress syndrome (ARDS), the 
severe form of ALI, are characterized by an acute onset of severe hypoxia pulmonary 
inﬁltration [7], pulmonary hypertension, edema and deteriorated gas exchange [8]. 
Indeed, sepsis is a potential risk factor for ALI and ARDS [5]. 
To date, the molecular mechanisms underlying the pathogenesis of sepsis-induced 
ALI are poorly defined and understood. We do know that endothelin (ET)-1, a potent 
endogenous vasoconstrictor and pro-inflammatory peptide [9,10], is actively involved in 
the pathogenesis of sepsis and the sepsis-associated organ dysfunction, as well as the 
associated complications [11], as evidenced by data from recent studies. Specifically, 
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plasma levels of ET-1 are elevated in various sepsis animal models, including septic 
patients [12–15] and a clear correlation has been observed between ET plasma levels 
and morbidity/mortality in septic patients. These observations implicates ET in the 
pathogenesis of septic shock in human [16,17]. Further, ET-1 likely has a direct role in 
the development and subsequent severity of ALI by increasing the pressure of 
pulmonary microvasculature during the first phase or hours of sepsis [18,19]. 
Interestingly, endothelin blocker, namely tezosentan, ameliorates pulmonary 
hypertension, lung edema, cardiac dysfunction, and arterial hypoxemia in an ovine 
model of endotoxin-induced lung injury [20]. In contrast, intravenous infusion of ET-1 
causes an elevation in pulmonary artery pressure and edema [21], implying a direct role 
of ET-1 in the pathogenesis of lung injury.  
Landiolol hydrochloride, an ultra-short-acting and highly cardio-selective beta-1 
blocker, with a half-life of 4 min, has been used in treating several acute medical 
disorders, including arrhythmias, during heart surgery [22], acute myocardial infarction 
[23], acute decompensated heart failure [24], and refractory electrical storm [25]. 
Ultra-short-acting β-blockers, such as landiolol, can influence heart rate but exert 
minimal effect on cardiac function. Besides, the potential effects of landiolol on rhythm 
control, landiolol also plays a protective role against ALI in a rat model of 
lipopolysaccharide (LPS)-induced systemic inflammation, which is associated with a 
reduction in high mobility group box 1 (HMGB-1) [26]. Very recently, we have 
demonstrated that landiolol is effective in improving acute liver injury of sepsis through 
the modulation of TNF (tumor necrosis factor-alpha)-α [27]. In addition, we have also 
shown that ET-1 is highly upregulated in kidney and heart tissues in LPS-administered 
rats [28,29] and landiolol has inhibitory effects on the upregulated levels of ET-1 in 
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both of these tissues. However, it is not known whether landiolol will equally exert  
protective effects in lung tissues during sepsis through the alteration of the ET-1 system. 
Indeed, in our previous study we have already reported elevated ET-1 levels in lung 
tissues during sepsis [30]. 
In the present study, we investigated whether landiolol hydrochloride, an ultra- 
short-acting β-blocker, can play an important role in attenuating LPS-induced ALI 
through the modulation of pulmonary ET-1. 
MATERIALS AND METHODS 
Male Wistar rats (200–250 g, 8 weeks old) were used in all experiments in the 
current study. Sepsis was induced by the intra-peritoneal (IP) administration of bacterial 
LPS from Escherichia coli 055: B5 (15 mg/kg), dissolved in sterile saline, as described 
previously [31–33]. A dose 15 mg/kg of LPS has been shown to induce morphological 
injures in lung [34] as shown in our dose response study. 
The total number of rats used in all the experiment was 45, which was randomized 
into three groups, namely: Group 1 (control, n = 15), group 2 (LPS, n = 15) and group 3 
(LPS + landiolol hydrochloride, n = 15). For group 1, sterile saline (2 ml/body) was 
administered at time 0h and then the rats were killed after 3h (control group). For group 
2, LPS at a dose of 15 mg/kg was administered at time 0h, and then the rats were killed 
after 3h (sepsis group). In group 3, landiolol hydrochloride was administered 
intravenously (100 µg/kg/min) for 15 min non-stop before LPS administration 
(landiolol treated sepsis group). The dose for landiolol was found to be the minimal 
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dose for normalizing the LPS-induced hyperdynamic state in the acute (early) phase 
(hours) of sepsis, as reported in our past study [28]. 
Nembutal (sodium pentobarbital, IP, 80 mg/kg body weight, routinely used in our 
lab) was used to kill all the rats at 3h, at the end of the experimental protocol. Blood gas 
analysis was also performed in the current study. The blood samples were collected 
from a polypropylene tube catheter inserted into the left carotid artery for blood gas 
analysis, and then lung tissues were carefully harvested, snap-frozen in liquid nitrogen, 
and stored at − 80 °C. All animals received proper care and the experimental procedures 
were approved by the Animal Care and Use Committee of University of Tsukuba prior 
to the study. 
Measurements of hemodynamic parameters 
Hemodynamic parameters were measured using a previously optimized 
methodology from our lab [27–35]. Briefly, rats were anesthetized with isoflurane 
inhalation (1.5%, 1 l/min) and a microtip pressure transducer catheter (SPC-320, Millar 
Instruments, Houston, TX, USA) was inserted into the left carotid artery at the end of 
the experimental protocol. Arterial blood pressure and heart rate (HR) were monitored 
with a pressure transducer (model SCK-590, Gould, Ohio, USA) and recorded with the 
use of a polygraph system (amplifier, AP-601G, Nihon Kohden, Tokyo, Japan; 
Tachometer, AT-601G, Nihon Kohden; and thermal-pen recorder, WT-687G, Nihon 
Kohden).  
Echocardiography 
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Echocardiography was performed using a Vevo 2100 high-frequency ultrasound 
system (VisualSonics, Inc., Ontario, Canada), which includes an integrated rail system 
for consistent positioning of the ultrasound probe [36] at the end of the protocol. The fur 
from the chest was shaved with an electrical clipper and a gel. The animals were then 
connected to an electrocardiogram (ECG). An optimal parasternal long axis (LAX) cine 
loop (i.e. visualization of both the mitral and aortic valves, and maximum distance 
between the aortic valve and the cardiac apex) of > 1000 frames/s was acquired using 
the ECG-gated kilohertz visualization technique. The probe was then rotated 90° and 
positioned 6 mm below the mitral annulus. Three parasternal short-axis (SAX) M-mode 
sequences were stored. Percent fractional shortening (% FS) was calculated in the 
M-mode image as FS = (EDD − ESD) / EDD, where EDD and ESD are the 
end-diastolic and end-systolic diameters, respectively. 
Lung wet-to-dry weight ratio 
Lung tissues were harvested, blotted dry and weighed in order to determine the 
weight of the lung in the wet state and the wet-to-dry weight ratio was calculated, as 
follows: the lung tissues were weighed; wrapped loosely in aluminum foil; dried in an 
oven at 80°C for 24h; and weighed again. Then the ratio lung wet-to-dry weight ratio 
was calculated. 
Histopathology examination 
After tissue harvest, the lungs were fixed in 4% buffered formalin solution, 
dehydrated, embedded in paraffin, and then sliced into 5-mm-thick sections to evaluate 
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lung micro-morphological injury. After deparaffinization, tissue sections were stained 
using standard hematoxylin and eosin (HE) staining method.  
Enzyme-linked immunosorbent assay  
The concentration of each respective protein/peptide, as described below under the 
plasma/serum and pulmonary tissue extracts section, was determined using the 
following kits: serum and lung levels of tumor necrosis factor alpha (TNF-α) and ET-1; 
plasma levels of IL-6 (R & D Systems, Minneapolis, MN), according to the 
manufacturer's protocol. These kits are already validated for the measurement of rat 
samples in our lab. 
RNA preparation and real-time quantitative polymerase chain reaction 
Total RNA samples from lung tissues were isolated using the Acid guanidinium 
thiocyanatephenol chloroform extraction with RNeasy (Qiagen, Tokyo, Japan). After 
RNA isolation, quantification and DNase I treatment, RNA was reverse transcribed to 
cDNA using Omniscript RT and the first-strand cDNA synthesis kit (Qiagen). The 
reaction was performed at 37 °C for 60 min. 
The mRNA expression levels of target genes were analyzed by real-time 
quantitative PCR using TaqMan probe and an ABI Prism 7700 sequence detector 
(PerkinElmer Applied Biosystems, Foster, CA). The gene-specific primers and TaqMan 
probes were synthesized from Primer Express version 1.5 software (PerkinElmer), 
according to the published cDNA sequences for each gene, as previously described 
[32,37]. The PCR mixture (25 µl total volume) consisted of forward and reverse primers 
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for each gene (PerkinElmer) at 450 nM each, FAM-labeled primer probes 
(PerkinElmer) at 200 nM, and TaqMan Universal PCR Master Mix (PerkinElmer). Each 
PCR amplification was performed in triplicate as follows: 1 cycle at 95 °C for 10 min 
and 40 cycles at 94 °C for 15 s and 60 °C for 1 min. The quantitative values of target 
mRNAs were normalized by glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
mRNA, because GAPDH mRNA expressions were more stable among all the samples 
than other internal controls, such as β-actin and 18S ribosomal RNA.  
Primers and probes are as follows:  
TNF-α forward: 5′-CCAGGAGAAAGTCAGCCTCCT-3′,  
TNF-α reverse: 5′-TCATACCAGGGCTTGAGCTCA-3′, and  
TNF-α probe: 5′-AGAGCCCTTGCCCTAAGGACACCCCT-3′;  
IL-6 forward primer: 5′-ACAGCCACTGCCTTCCCTAC-3′,  
IL-6 reverse: 5′-TCTCATTTCCAAGATCTCCC-3′, and  
IL-6 probe: 5′-CACAGAGGATACCACCCACA-3′;  
Hypoxia-inducible factor-1 alpha (HIF-1α) forward: 
5′-CTATGGAGGCCAGAAGAGGGTAT-3′,  
HIF-1α reverse: 5′-CCCACATCAGGTGGCTCATAA-3′, and  
HIF-1α probe: 5′-AGATCCCTTGAAGCTAG-3′,  
 9 
ET-1 forward: 5′-TCTACTTCTGCCACCTGGACAT-3′;  
ET-1 reverse: 5′-GAAGGGCTTCCTAGTCCATACG-3′, and  
ET-1 probe: 5′-CATCTGGGTCAACACTCC-3′;  
ET-A forward: 5′-GAATCTCTGCGCTCTCAGTGT-3′,  
ET-A reverse: 5′-GAGACAATTTCAATGGCGGTAATCA-3′, and  
ET-A probe: 5′-CAGGAAGCCACTGCTCT-3′;  
ET-B forward: 5′-GCTGGTGCCCTTCATACAGA-3′,  
ET-B reverse: 5′-CTTAGAGCACATAGACTCAACACTGT-3′, and  
ET-B probe: 5′-ATCCCCACAGAAGCCT-3′;  
GAPDH forward: 5′-GTGCCAAAAGGGTCATCATCTC-3′,  
GAPDH reverse: 5′-GGTTCACACCCATCACAAACATG-3′, and  
GAPDH probe: 5′-TTCCGCTGATGCCCC-3′. 
Statistical analysis 
The results were expressed as mean ± SE, and for parametric distribution, analysis 
of variance test was used. For non-parametric distribution, Kruskal-Wallis test, followed 
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by Steel-Dwass for multiple comparisons was used. A P < 0.05 was considered 
statistically significant for all parameters. 
 
RESULT 
Blood gas analysis results 
Table 1 shows the data of blood gas analysis in the current experimental setting. 
pH was not significantly different among the three groups (Table 1). Arterial PaO2 was 
significantly decreased in LPS-administered rats compared to control group and 
landiolol treatment significantly increased the levels of arterial PaO2 in septic rats 
(Table 1). However, arterial PaCO2 was not significantly changed among the three 
groups. Blood lactate concentrations were elevated with LPS administration and 3h 
treatment with landiolol partly normalized the elevated levels of lactate in 
LPS-administered rats (Table 1). HCO3- and base excess were not significantly changed 
among the three groups (Table 1). 
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Hemodynamic changes in current experiments: 
We assessed the hemodynamic parameters in the rats after LPS administration. As 
shown in Table 2, both the levels of the systolic and diastolic blood pressure were 
significantly lower at 3h after LPS administration compared to that of the control group 
and was unaffected by landiolol treatment. Landiolol significantly decreased the 
elevated heart rate in LPS-administered animals (Table 2).% FS was also significantly 
increased (hyperkinetic) in LPS-administered group compared to that of control group, 
and a 3 h long treatment of LPS-administered rats with landiolol significantly reversed 
the elevated % FS (Table 2). 
Morphological evaluation 
In the LPS-administered group, lung tissues showed thickening of alveolar, 
congestion formation and infiltration by neutrophils, but (these morphological 
abnormalities) were absent in the lung of the control group (Figure 1A). Landiolol 
treatment for 3h significantly improved the lung congestion in septic rats (Figure 1A).  
Wet-to-dry weight ratio of lung tissue was calculated in each study group in the present 
experiment. In the LPS-administered septic group, pulmonary wet-to-dry weight ratios 
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were significantly higher compared to that of the control group and a 3 h treatment of 
septic animals with landiolol significantly normalized the pulmonary wet-to-dry ratio 
(Figure 1B).  
Evaluation of expression of ET-1 system in lung tissue 
Levels of ET-1 peptide were also evaluated in the current experimental setting 
(Figure 2A). ET-1 peptide expression was significantly increased in the lung tissue 
(about 2-fold) after LPS administration compared to the control group and landiolol 
treatment for 3h significantly normalized the elevated levels of pulmonary ET-1 peptide 
in septic rats (Figure 2A). While levels of pulmonary ET-1 in septic rats was greatly 
ameliorated following the 3h treatment by landiolol, landiolol treatment failed to 
normalize the elevated levels of plasma ET-1 in septic rats (Table 3). Prepro ET-1 
mRNA levels were also elevated in lung tissue in the LPS-administered group 
compared to the control group. However, landiolol treatment normalized the elevated 
levels of prepro ET-1 mRNA in septic lung tissues (Figure 2B). Moreover, ET-A 
receptor mRNA expression in lung tissue was also elevated in the LPS administration 
group compared to the control group, and landiolol treatment normalized the elevated 
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levels of ET-A receptor mRNA (Figure 2C) in septic rats. In contrast, ET-B receptor 
mRNA expression in lung tissue significantly decreased in the LPS administration 
group compared to the control group, and landiolol treatment failed to normalize the 
decreased levels of ET-B receptor mRNA in septic pulmonary tissues (Figure 2D).  
Evaluation of expression levels of inflammatory cytokine (TNF-alpha and IL-6)  
Both the upregulated plasma levels of potential inflammatory cytokines, TNF-α 
and IL-6 were unchanged with the treatment of landiolol in septic rats (Table 3). We 
also evaluated the expression patterns of mRNA and protein of TNF-α, the key 
inflammatory cytokine in lung tissues during sepsis. Levels of both protein and mRNA 
(TNF-α) were significantly higher in septic lungs compared to the control group and a 3 
h treatment of septic rats with landiolol could not normalize the elevated levels of TNF 
in lungs (Figure 3A, 3B). In the current experimental setting, the expression levels of 
IL-6, another highly potent inflammatory cytokine, had parallel expression pattern as 
TNF-α (Figure 3C), which was upregulated in LPS-administered rats and was 
unchanged following landiolol treatment.  
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Evaluation of expression levels of HIF-1α 
In addition, to clarify whether LPS administration induces any hypoxic condition 
in pulmonary tissues, we examined the mRNA expression levels of HIF-1α in lung 
tissue in present study. HIF-1α mRNA expression levels were also increased in the LPS 
administration group in lung tissues, but landiolol treatment did not normalize the 
elevated pulmonary levels of HIF-1α (Figure 3D). 
 
Discussion 
The present study is the first to demonstrate the normalization of elevated ET 
levels in rat pulmonary tissues by an ultrashort acting beta blocker (landiolol 
hydrochloride) during the early stages (hours) of sepsis. Further, this phenomenon (of 
landiolol on pulmonary ET-1 level) is also accompanied by an improvement in the 
morphology of the septic lung tissues. Here, we also show that pre-treatment of 
LPS-administered rats with landiolol for 3h normalized both the diminished levels of 
PaO2 and enhanced levels of blood lactate in early sepsis. In contrast, these observed 
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pulmonary ameliorations (molecular and morphological) in septic rats induced by 
landiolol are not associated with alteration in levels of inflammatory cytokines (TNF-α, 
IL-6) and hypoxia marker (HIF-1) under the current experimental setting.  
A previous study has reported that LPS increases heart rate and % FS in rats 3h 
post administration and that if these (septic) animals are treated with landiolol these 
altered conditions (HR and % FS) are normalized [28,29]. It is interesting that while 
landiolol was able to decrease % FS and HR in septic rats, as reported previously, it 
(landiolol) had no significant effect on systolic and diastolic blood pressure under the 
current experimental setting. In fact, landiolol’s effect on blood pressure was lesser than 
esmolol, an ultra- short-acting β-blocker [38,39]. It is likely that landiolol’s ability to 
attenuate the LPS-induced hyperdynamic state in septic rats may be linked to its 
(landiolol) partial normalization of elevated blood lactate concentrations in early sepsis. 
The present study demonstrates landiolol’s ability to improve PaO2 during the 
early phase (hours) of sepsis in rats, as well as reduction of congestion and 
normalization of the wet-to-dry ratio in lungs compared to the untreated group. These 
findings are significant since LPS has been shown to induce edema formation, 
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infiltration of interstitial tissue by neutrophils, and reduction of alveolar spaces in lungs, 
12h post-treatment [40] and, importantly, these (same) morphological injuries 
diminished after administration of landiolol [26]. Thus, based on the current data, we 
speculate that landiolol is equally effective in eliminating acute septic-induced 
pulmonary tissue injuries through the reduction of congestion, and, ultimately, leads to 
a decrease in pulmonary wet-to-dry weight ratio and improvement in arterial PaO2. 
ET-1 is a potent vasoconstrictor and pro-inflammatory peptide and has previously 
been implicated in the pathogenesis of sepsis and sepsis-induced MODS [41,42]. 
Therefore, the present data, showing an increase in the plasma levels of ET-1, are 
consistent with data obtained from earlier studies [35] from our lab and others 
[16,17,43]. This observed increase in levels of plasma ET-1 in septic animals may be 
due to a combination of enhanced ET-1 synthesis, as well as impairment in ET 
clearance in renal and pulmonary tissues [16]. ETs is also known to play an important 
role in the pathogenesis of sepsis-induced ALI and vascular failure [44] and for this 
reason ET blockers have been shown to have a protective effect in ALI [45–49] and 
MODS in sepsis. Because of these biological effects ETs have attracted significant 
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research interest in the development of novel therapeutic and diagnostic tools for sepsis 
and other systemic inflammatory response syndromes (SIRS) and disorders 
[12,50,51,52]. In our present study, we also found the elevated ET-1 level in lung 
tissues at 3h after LPS administration at hyperdynamic state in septic rats as consistent 
to past studies [30,35]. Lastly, although levels of pulmonary ET-1 were found to be 
elevated during the early phases (hours) of sepsis, its two receptors, ET-A and –B were 
differentially expressed, i.e., levels of ET-A receptor were up regulated while that of 
ET-B receptor were down regulated in lung tissue of septic rats. These differential 
expression patterns (of ET receptors) in septic lung were consistent with data from past 
studies [30,35]. 
The present study is the first time to demonstrate the amelioration of an altered ET 
system and ET-A but not ET-B in lung tissue of septic rats following a 3h treatment of 
landiolol. We intend to examine in depth the specific mechanisms underlying the 
differential effects of landiolol on the expression of pulmonary ET receptor subtypes in 
future using genetically altered/manipulated experimental animals, such as the ET 
receptor knockout mice. In wrapping up, we speculate that landiolol may normalize the 
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altered ET-1 system using a similar pathway or mechanism as the non-selective ET 
receptor antagonist, bosentan [45], and it (landiolol) may also lead to the repair of lung 
injury in ALI in rat models, as demonstrated in the current study. However, future 
studies are required to provide more data that supports our current speculation.  
Landiolol has been shown to be effective in preventing ALI in LPS administered 
rat through the attenuation of an inflammatory marker, HMGB-1 [26], as well in 
repairing lung injury in the early phases (hours) of sepsis. Surprisingly, landiolol could 
not normalize the up regulated levels of pulmonary TNF-α and IL-6, two potential 
pro-inflammatory cytokines, back to baseline levels in septic rats. Based on these 
current findings, it appears that the observed reversal effects of landiolol on the elevated 
levels of ET-1 in pulmonary tissue does not depend on the expression of TNF-α and 
IL-6 in septic rats. In contrast, following landiolol treatment, the liver tissue of septic 
rats gets repairs during the acute phase of liver injury and the up regulated levels of 
hepatic TNF-α are normalized in the same experimental setting as in the current study 
[27]. Thus it can be concluded that landiolol-induced repair in organ injury during the 
acute phase of sepsis involves the normalization of differential organ-specific signaling 
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pathways. It is interesting to note that in both of our studies (current and past study 
[27]), landiolol failed to normalize the up regulated levels of plasma TNF-α, while 
exerting differential effects on the levels of TNF-α in various organs of septic rats. 
Further, although elevated HIF-1α has been shown to be normalized in kidney tissues of 
septic rats, in addition to the amelioration of the up regulated levels of renal ET-1 by 
landiolol treatment [28], the reversal effects of landiolol on the up regulated levels of 
pulmonary ET-1 and HIF-1α had a different outcome in the present study from that of 
the renal tissues. The LPS-induced elevated levels of HIF-1α in lung tissue 
demonstrated by the present study may imply the presence of hypoxia. Future studies 
are undoubtedly essential in dissecting the organ-specific effects of landiolol on various 
signaling pathways in septic rats, including the very early stages of sepsis. Of note, no 
significant change in blood pressure of LPS-administered rats was observed after 
landiolol treatment in the current study. These findings imply that the normalization of 
the elevated levels of pulmonary ET-1 in sepsis by landiolol is independent of blood 
pressure changes. Mechanistic studies in future are essential in exploring and 
uncovering the underlying mechanism of the current findings and in shedding more 
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insights on the potential protective effects that landiolol may exert on the lung in early 
sepsis.  
Conclusion 
The present study demonstrates that landiolol hydrochloride, a selective 
ultra-short-acting β-blocker, ameliorates lung injury in a rat model during early sepsis. 
Landiolol possibly exerts such an effect through the suppression of elevated levels of 
pulmonary ET-1 but not levels of TNF-α and HIF-1α. These current findings may create  
news areas to explore beneficial clinical and preventive applications of landiolol in 
sepsis-induced multiple organ dysfunction syndrome, particularly in the acute phase of 
lung injury. 
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Table 1 Blood gas analysis parameters 
Parameters  Control LPS LPS+Landiolol 
pH 7.39 ± 0.01 7.37 ± 0.02 7.38 ± 0.01 
PaO2 (torr) 102.8 ± 2.2 84.2 ± 4.7＊ 102.4 ± 3.9♯ 
PaCO2 (torr) 40.2 ± 1.4 40.9 ± 2 37.2 ± 2 
Base Excess (mmol/l) 0.5 ± 0.5 -2.8 ± -0.7＊ -3.9  ± 0.7＊ 
Lactate (mmol/l) 1.4 ± 0.1 2.8 ± 0.2＊ 2 ± 0.1♯ 
HCO3- (mmMol/l) 25.3 ± 0.5 21.4 ± 0.7＊ 20.7 ± 0.8＊ 
Data are mean ± SE: ＊p< 0.05 vs. Control; ♯p< 0.05 vs. LPS 
Abbreviations: LPS; lipopolysaccharide 
 
Table 2 Hemodynamics and echocardiogram 
Parameters Control LPS  LPS+Landiolol 
Systolic BP (mmHg) 125.6  ± 3.2  93.2  ± 6.6＊ 98.5  ± 5＊ 
Diastolic BP (mmHg) 99.8  ± 3.1 72.3  ± 5.8＊ 75.5  ± 4.8＊ 
Heart Rate (bpm) 468.7 ± 19 501.2 ± 16.2＊ 439.9  ± 6.5♯ 
Fractional Shortening (%) 40.3  ± 1.3 45.1 ± 1.2＊ 41.2  ± 1♯ 
Data are mean ± SE; ＊p< 0.05 vs. Control; ♯p< 0.05 vs. LPS 
Abbreviations: BP; blood pressure; LPS; lipopolysaccharide 
 
Table 3 Plasma Tumor Necrosis Factor (TNF)-α, Endothelin-1 (ET-1) and 
Interleukin-6 (IL-6) levels 
  Control LPS LPS+Landiolol 
TNF- (plasma, pg/ml) 15.7 ± 7 180 ± 40＊ 184.3 ± 30.1＊ 
ET-1 (plasma, pg/ml) 3.8 ± 0.4 34 ± 3.3＊ 32.5 ± 3.3＊ 
IL-6 (plasma, pg/ml) 18.3 ± 1.9 29 ± 3.3＊ 26.7 ± 3.7＊ 
 
Data are mean ± SE; ＊p< 0.05 vs. Control; ♯p< 0.05 vs. LPS 
Abbreviations: LPS; lipopolysaccharide 
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Figure legends 
 
Figure 1: A; Morphological findings by hematoxylin and eosin staining (HE) inlung 
tissues in control rats, 3h after lipopolysaccharide (LPS) administration, and 3h after 
LPS plus landiolol hydrochloride administration. Magnification, ×320.B; Pulmonary 
wet-to-dry weight ratio in control rats, 3h after lipopolysaccharide (LPS) administration, 
and 3h after LPS plus landiolol hydrochloride administration. Wet-to-dry weight ratios 
were determined for each experimental group. Values are mean ± SE (n = 5). * p< 0.05 
vs. Control, # p< 0.05 vs. LPS 
 33 
 
Figure 2: Peptide and mRNA expression levels of ET-1 (A and B),mRNA expression 
levels of  ET-A (C), ET-B (D) receptors inlung tissues in control, 3h LPS-administered 
rats, and landiolol treated 3h LPS-administered rats.ET-1 peptide was measured by 
ELIZA. mRNA expression level was determined by Real Time PCR. The control was 
normalized as 100%. Values are mean ± SE (n = 15). *p< 0.05 vs. Control, # p< 0.05 vs. 
LPS 
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Figure 3: mRNA and protein expression levels of TNF-α (A and B), and mRNA 
expression levels of IL-6 (C), HIF-1α (D) in lung tissues in control, 3h 
LPS-administered rats, and landiolol treated 3h LPS-administered rats. TNF-α protein 
was measured by ELIZA. mRNA expression level was determined by Real Time PCR. 
The control was normalized as 100%. Values are mean ± SE (n = 15). * p< 0.05 vs. 
Control, # p< 0.05 vs. LPS 
 
